Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001493152-20-018396
Filing Date
2020-09-28
Accepted
2020-09-28 06:10:33
Documents
56
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 form10-k.htm 10-K 845169
2 image_001.jpg GRAPHIC 69800
3 ex10-6.htm EX-10.6 16508
4 ex31-1.htm EX-31.1 11549
5 ex31-2.htm EX-31.2 10766
6 ex32-1.htm EX-32.1 4113
7 ex32-2.htm EX-32.2 4186
  Complete submission text file 0001493152-20-018396.txt   3442126

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE FILE nxen-20200630.xml EX-101.INS 363291
9 XBRL SCHEMA FILE nxen-20200630.xsd EX-101.SCH 44864
10 XBRL CALCULATION FILE nxen-20200630_cal.xml EX-101.CAL 36965
11 XBRL DEFINITION FILE nxen-20200630_def.xml EX-101.DEF 150845
12 XBRL LABEL FILE nxen-20200630_lab.xml EX-101.LAB 300250
13 XBRL PRESENTATION FILE nxen-20200630_pre.xml EX-101.PRE 218719
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-K | Act: 34 | File No.: 000-55320 | Film No.: 201201928
SIC: 2834 Pharmaceutical Preparations